BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 59 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,550 | -1.2% | 15,000 | 0.0% | 0.00% | – |
| Q2 2023 | $14,734 | -4.3% | 15,000 | 0.0% | 0.00% | – |
| Q1 2023 | $15,390 | -3.3% | 15,000 | 0.0% | 0.00% | – |
| Q4 2022 | $15,920 | +6.1% | 15,000 | 0.0% | 0.00% | – |
| Q3 2022 | $15,000 | 0.0% | 15,000 | 0.0% | 0.00% | – |
| Q2 2022 | $15,000 | 0.0% | 15,000 | 0.0% | 0.00% | – |
| Q1 2022 | $15,000 | -6.2% | 15,000 | 0.0% | 0.00% | – |
| Q4 2021 | $16,000 | +6.7% | 15,000 | 0.0% | 0.00% | – |
| Q3 2021 | $15,000 | -6.2% | 15,000 | 0.0% | 0.00% | – |
| Q2 2021 | $16,000 | +6.7% | 15,000 | 0.0% | 0.00% | – |
| Q1 2021 | $15,000 | -6.2% | 15,000 | 0.0% | 0.00% | – |
| Q4 2020 | $16,000 | – | 15,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SHENKMAN CAPITAL MANAGEMENT INC | 29,791,000 | $29,160,000 | 1.77% |
| PFM Health Sciences, LP | 45,910,000 | $45,566,000 | 1.74% |
| Cheyne Capital Management (UK) LLP | 1,500,000 | $1,486,000 | 1.26% |
| SSI INVESTMENT MANAGEMENT LLC | 11,878,000 | $11,761,000 | 0.74% |
| Sonora Investment Management Group, LLC | 6,550,000 | $6,527,000 | 0.62% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 34,005,000 | $33,750,000 | 0.60% |
| PALISADE CAPITAL MANAGEMENT, LP | 10,703,000 | $10,595,000 | 0.29% |
| MACKAY SHIELDS LLC | 11,419,000 | $11,304,000 | 0.27% |
| BNP Paribas Asset Management Holding S.A. | 4,175,000 | $70,578,000 | 0.27% |
| RWC Asset Management LLP | 8,200,000 | $8,143,000 | 0.26% |